Similarly to the use of the AFP promoter and enhancer for HCC, prostate-specific antigen promoters have been used for prostate cancer (19), while E2F and telomerase reverse transcriptase promoters are used for various types of tumors (20,21). Here, KLK3 is linked to prostate carcinoma.